About
Intranasal Drug Delivery
Areas of Focus
Categories
Drug Delivery & FormulationMiddle East
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
793
By Phase
PHASE2/PHASE3: 1PHASE1/PHASE2: 1NA: 1PHASE1: 2
By Status
COMPLETED: 4ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07045701Lead Sponsor
FMXIN002 in Patients at Risk of Anaphylaxis
PHASE2/PHASE3Enrolling by invitation
30 participants
Started: Jun 12, 2025 · Completed: Jul 12, 2026
NCT06205134Lead Sponsor
Comparative Bioavailability of Intranasal Epinephrine
PHASE1/PHASE2Completed
12 participants
Started: Aug 22, 2023 · Completed: Feb 5, 2024
NCT05252468Lead Sponsor
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
NACompleted
693 participants
Started: May 19, 2021 · Completed: Dec 2, 2021
NCT04713709Lead Sponsor
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder
PHASE1Completed
46 participants
Started: Jan 31, 2021 · Completed: Oct 10, 2021
NCT04696822Lead Sponsor
Bioavailability of Nasal Epinephrine
PHASE1Completed
12 participants
Started: Nov 1, 2020 · Completed: Sep 28, 2021
Locations (1)
Headquarters
Tel Aviv, Israel
Map
Loading map...